Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8107636 | 0.94 | PRMT6 (0.45) | PRMT6THRBTP53ADRA1DNPC1 | |
| SCHEMBL1040627 | 0.86 | — | — | |
| SCHEMBL4422429 | 0.84 | HPGD (0.33) | ALDH1A1HPGD | |
| SCHEMBL9508187 | 0.82 | PRMT6 (0.37) | PRMT6THRBTP53ADRA1DNPC1 | |
| SCHEMBL1523312 | 0.81 | — | — | |
| SCHEMBL23665620 | 0.81 | PRMT6 (0.58) | PRMT6THRBTP53ADRA1DNPC1 | |
| SCHEMBL9479561 | 0.80 | PRMT6 (0.48) | PRMT6THRBTP53ADRA1DMEN1 | |
| SCHEMBL21722994 | 0.78 | PRMT6 (0.47) | PRMT6THRBTP53ADRA1DNPC1 | |
| SCHEMBL79698 | 0.78 | PRMT6 (0.47) | PRMT6THRBTP53ADRA1DNPC1 | |
| SCHEMBL19438869 | 0.78 | PRMT6 (0.47) | PRMT6NPC1RAB9ASMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180170918-A1 | METHODS OF SYNTHESIZING A DIFLUOROLACTAM ANALOG | CAYMAN CHEMICAL CO INC (US) | 2018-06-21 | — | — | US | disclosed |
| US-9914725-B2 | Methods of synthesizing a difluorolactam analog | CAYMAN CHEMICAL COMPANY, INC. (US) | 2018-03-13 | — | — | US | disclosed |
| EP-2168944-B1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2016-05-11 | — | — | EP | disclosed |
| US-20160060253-A1 | METHODS OF SYNTHESIZING A DIFLUOROLACTAM ANALOG | CAYMAN CHEMICAL COMPANY, INC. | 2016-03-03 | — | — | US | disclosed |
| US-8129361-B2 | Amine compound and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-03-06 | — | — | US | disclosed |
| US-8129361-B2 | Amine compound and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-03-06 | — | — | US | disclosed |
| US-8129361-B2 | Amine compound and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-03-06 | — | — | US | disclosed |
| US-20100179216-A1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-07-15 | — | — | US | disclosed |
| US-20100179216-A1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-07-15 | — | — | US | disclosed |
| US-20100179216-A1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-07-15 | — | — | US | disclosed |
| EP-2168944-A1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180170918-A1 | METHODS OF SYNTHESIZING A DIFLUOROLACTAM ANALOG | PTGER4, PTGER1, PTGIR | PRMT6 840/4885THRB 1231/4885TP53 3135/4885 |
| US-20100179216-A1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | HLA-B, HLA-A, HLA-C | PRMT6 574/4885THRB 1455/4885TP53 968/4885 |
| US-20160060253-A1 | METHODS OF SYNTHESIZING A DIFLUOROLACTAM ANALOG | PTGER4, PTGER1, PTGIR | PRMT6 840/4885THRB 1231/4885TP53 3135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.